Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD17B10 | Q99714 | 7/20 | 1.00 |
| ▸ | MEN1 | O00255 | 6/20 | 1.00 |
| ▸ | KMT2A | Q03164 | 6/20 | 1.00 |
| ▸ | KDM4E | B2RXH2 | 6/20 | 1.00 |
| ▸ | CYP1A2 | P05177 | 3/20 | 1.00 |
| ▸ | CYP2D6 | P10635 | 3/20 | 1.00 |
| ▸ | TP53 | P04637 | 3/20 | 1.00 |
| ▸ | CYP3A4 | P08684 | 2/20 | 1.00 |
| ▸ | TEAD4 | Q15561 | 2/20 | 1.00 |
| ▸ | HTR1A | P08908 | 1/20 | 1.00 |
| ▸ | ADRA2A | P08913 | 1/20 | 1.00 |
| ▸ | CHRM1 | P11229 | 1/20 | 1.00 |
| ▸ | MAOA | P21397 | 1/20 | 1.00 |
| ▸ | DRD1 | P21728 | 1/20 | 1.00 |
| ▸ | SLC6A2 | P23975 | 1/20 | 1.00 |
| ▸ | TEAD1 | P28347 | 1/20 | 1.00 |
| ▸ | SLC6A4 | P31645 | 1/20 | 1.00 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 1.00 |
| ▸ | KCNH2 | Q12809 | 1/20 | 1.00 |
| ▸ | TEAD2 | Q15562 | 1/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Pirlindole SCHEMBL29500947 | 1.00 | HSD17B10 (1.00) | HSD17B10MEN1KMT2AKDM4ECYP1A2 | |
| Pirlindole SCHEMBL373564 | 1.00 | HSD17B10 (1.00) | HSD17B10MEN1KMT2AKDM4ECYP1A2 | |
| Pirlindole SCHEMBL18878061 | 1.00 | HSD17B10 (1.00) | HSD17B10MEN1KMT2AKDM4ECYP1A2 | |
| Pirlindole SCHEMBL4157397 | 0.99 | HSD17B10 (0.97) | HSD17B10MEN1KMT2AKDM4ECYP1A2 | |
| Pirlindole SCHEMBL1649683 | 0.97 | HSD17B10 (0.95) | HSD17B10MEN1KMT2AKDM4ECYP1A2 | |
| SCHEMBL4152460 | 0.94 | HSD17B10 (1.00) | HSD17B10MEN1KMT2AKDM4ECYP1A2 | |
| Pirlindole SCHEMBL30984462 | 0.92 | HSD17B10 (1.00) | HSD17B10MEN1KMT2AKDM4ECYP1A2 | |
| Pirlindole SCHEMBL3761340 | 0.92 | HSD17B10 (1.00) | HSD17B10MEN1KMT2AKDM4ECYP1A2 | |
| Pirlindole SCHEMBL17241165 | 0.83 | HSD17B10 (0.68) | HSD17B10MEN1KMT2AKDM4ECYP1A2 | |
| SCHEMBL13702963 | 0.82 | KMT2A (0.98) | HSD17B10MEN1KMT2AKDM4ECYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3612534-B1 | PROCESS FOR THE PREPARATION OF PIPERAZINE RING FOR THE SYNTHESIS OF PYRAZINOCARBAZOLE DERIVATIVES | TECNIMEDE SOCIEDADE TECNICO MEDICINAL SA (PT) | 2021-12-22 | — | — | EP | disclosed |
| US-11008327-B2 | Processes for the preparation of pharmaceutically acceptable salts of (R)-Pirlindole and (S)-Pirlindole | TECNIMEDE, SOCIEDADE TÉCNICO-MEDICINAL, SA (PT) | 2021-05-18 | — | — | US | disclosed |
| US-11008328-B2 | Processes for the preparation of pharmaceutically acceptable salts of (R)-Pirlindole and (S)-Pirlindole | TECNIMEDE, SOCIEDADE TÉCNICO-MEDICINAL, SA (PT) | 2021-05-18 | — | — | US | disclosed |
| US-20200190098-A1 | PROCESS FOR THE PREPARATION OF PIRLINDOLE ENANTIOMERS AND ITS SALTS | TECNIMEDE, SOCIEDADE TÉCNICO-MEDICINAL, SA (PT) | 2020-06-18 | — | — | US | disclosed |
| US-20200131186-A1 | PROCESS FOR THE PREPARATION OF PIPERAZINE RING FOR THE SYNTHESIS OF PYRAZINOCARBAZOLE DERIVATIVES | TECNIMEDE, SOCIEDADE TÉCNICO-MEDICINAL, SA (PT) | 2020-04-30 | — | — | US | disclosed |
| US-20180111944-A1 | (R)-PIRLINDOLE AND ITS PHARMACEUTICALLY ACCEPTABLE SALTS FOR USE IN MEDICINE | TECNIMEDE SOCIEDADE TECNICO-MEDICINAL S.A. (PT) | 2018-04-26 | — | — | US | disclosed |
| US-20180111944-A1 | (R)-PIRLINDOLE AND ITS PHARMACEUTICALLY ACCEPTABLE SALTS FOR USE IN MEDICINE | TECNIMEDE SOCIEDADE TECNICO-MEDICINAL S.A. (PT) | 2018-04-26 | — | — | US | disclosed |
| EP-3054950-B1 | (R)-PIRLINDOLE AND ITS PHARMACEUTICALLY ACCEPTABLE SALTS FOR USE IN MEDICINE | TECNIMEDE-SOCIEDADE TECNICO-MEDICINAL S A (PT) | 2017-08-02 | — | — | EP | disclosed |
| US-20170145015-A1 | (R)-PIRLINDOLE AND ITS PHARMACEUTICALLY ACCEPTABLE SALTS FOR USE IN MEDICINE | TECNIMEDE SOCIEDADE TECNICO-MEDICINAL S.A. (PT) | 2017-05-25 | — | — | US | disclosed |
| US-20170145015-A1 | (R)-PIRLINDOLE AND ITS PHARMACEUTICALLY ACCEPTABLE SALTS FOR USE IN MEDICINE | TECNIMEDE SOCIEDADE TECNICO-MEDICINAL S.A. (PT) | 2017-05-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200190098-A1 | PROCESS FOR THE PREPARATION OF PIRLINDOLE ENANTIOMERS AND ITS SALTS | PIR, DRD1, DRD4 | HSD17B10 918/4885MEN1 3507/4885KMT2A 3373/4885 |
| US-20180111944-A1 | (R)-PIRLINDOLE AND ITS PHARMACEUTICALLY ACCEPTABLE SALTS FOR USE IN MEDICINE | PIR, OPRD1, OPRL1 | HSD17B10 2690/4885MEN1 4153/4885KMT2A 4743/4885 |
| US-11008327-B2 | Processes for the preparation of pharmaceutically acceptable salts of (R)-Pirlindole and (S)-Pirlindole | PIR, DRD5, DRD1 | HSD17B10 1569/4885MEN1 4194/4885KMT2A 4025/4885 |
| US-20200131186-A1 | PROCESS FOR THE PREPARATION OF PIPERAZINE RING FOR THE SYNTHESIS OF PYRAZINOCARBAZOLE DERIVATIVES | PIR, CYP3A5, DRD5 | HSD17B10 1906/4885MEN1 4435/4885KMT2A 2684/4885 |
| US-20170145015-A1 | (R)-PIRLINDOLE AND ITS PHARMACEUTICALLY ACCEPTABLE SALTS FOR USE IN MEDICINE | PIR, OPRD1, OPRL1 | HSD17B10 2690/4885MEN1 4153/4885KMT2A 4743/4885 |
| US-11008328-B2 | Processes for the preparation of pharmaceutically acceptable salts of (R)-Pirlindole and (S)-Pirlindole | PIR, DRD1, DRD5 | HSD17B10 1239/4885MEN1 2632/4885KMT2A 4560/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.